Articles & Publications , Dr. Andrew Lewis , GLP-1 Therapeutics , Oral Peptides

Video Interview: Dr. Andrew Lewis Discusses CMC Challenges for GLP-1 and Oral Peptides with PharmTech Europe

PharmTech.com and Pharmaceutical Technology Europe logos

In this video interview with PharmTech Europe, Dr. Andrew Lewis, Chief Scientific Officer at Quotient Sciences, discussed the CMC challenges with GLP-1 and oral peptides during his attendance at CPHI Milan.

Watch the recent video with PharmTech Europe and Andy Lewis — Watch a recent video with PharmTech Europe and Andy Lewis.

Dr. Lewis talked about the chemistry, manufacturing, and control (CMC) challenges encountered during the development of glucagon-like peptide 1 (GLP-1) and oral peptides.

Watch the full video and read the article on PharmTech Europe.

Latest news from Quotient Sciences

More News

Articles & Publications, John McDermott, Dr. Andrew Lewis, Artificial Intelligence How AI Is Transforming Formulation Development Through Predictive Design By: John McDermott and Andy Lewis

News & Announcements, Nottingham, UK, Artificial Intelligence, Translational Pharmaceutics®, Formulation Development Quotient Sciences and Acesion Pharma Announce Collaboration on AI-Enhanced Formulation Development to Advance Atrial Fibrillation Pipeline By: Dr. Andrew Lewis

News & Announcements, Artificial Intelligence Balancing Human Expertise and Artificial Intelligence in Drug Development

More News

Your breakthrough therapy deserves momentum, and every day matters. Start a conversation with us today.